💊
Betmiga
mirabegron
Überaktive Harnblase
✅ Autorisiert
✅
Keine aktiven Warnungen
Dieses Arzneimittel unterliegt derzeit keinen Lieferengpässen, Sicherheitshinweisen oder Rückrufen.
Wofür es verwendet wird
Overactive bladder in adults Betmiga prolonged-release tablets are indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Neurogenic detrusor overactivity in the paediatric population Betmiga prolonged release tablets are indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.
⚠️ Patientensicherheit
No
Offizielle EMA-Seite
https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga